|
|
|
|
4 Department of Animal Science, 5 Department of Veterinary Physiology and Pharmacology, and 6 Department of Statistics, Texas A&M University, College Station, TX, 77843; 7 Department of Animal and Food Sciences, Texas Tech University, Lubbock, TX 79409; and 8 Department of Systems Biology and Translational Medicine, Texas A&M Health Science Center, College Station, TX 77843
* To whom correspondence should be addressed. E-mail: g-wu{at}tamu.edu.
Anticipating the future use of arginine to enhance fetal and neonatal growth as well as to treat diabetes and obesity, we performed studies in pigs, rats, and sheep to determine the pharmacokinetics of orally or i.v. administered arginine and the safety of its chronic supplementation. Our results indicate that all 3 species rapidly catabolized the supplemental arginine. The elevated circulating concentrations of arginine generally returned to baseline levels within 45 h after administration, with the rates varying with the age and physiological status of the animals. The clearance of arginine was greater in pregnant than in nonpregnant animals, in young than in adult animals, in lean than in obese animals, and in type-1 diabetic than in nondiabetic animals. I.v. administration of arginine-HCl to pregnant ewes (at least 0.081 g arginine·kg body weight1·d1) did not result in any undesirable treatment-related effect. Neonatal pigs, growing-finishing pigs, pregnant pigs, and adult rats tolerated large amounts of chronic supplemental arginine (e.g. 0.62, 0.32, 0.21, and 2.14 g·kg body weight1·d1, respectively) administered via enteral diets without the appearance of any adverse effect. On the basis of the comparative studies and a consideration of species differences in food intake per kilogram body weight, we estimate that a 70-kg human subject should be able to tolerate long-term parenteral and enteral supplemental doses of 6 and 15 g/d arginine, respectively, in addition to a basal amount of arginine (46 g/d) from regular diets.
This article has been cited by other articles:
![]() |
A. Lassala, F. W. Bazer, T. A. Cudd, P. Li, X. Li, M. C. Satterfield, T. E. Spencer, and G. Wu Intravenous Administration of L-Citrulline to Pregnant Ewes Is More Effective Than L-Arginine for Increasing Arginine Availability in the Fetus J. Nutr., April 1, 2009; 139(4): 660 - 665. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zeng, F. Wang, X. Fan, W. Yang, B. Zhou, P. Li, Y. Yin, G. Wu, and J. Wang Dietary Arginine Supplementation during Early Pregnancy Enhances Embryonic Survival in Rats J. Nutr., August 1, 2008; 138(8): 1421 - 1425. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhan, D. Ou, X. Piao, S. W. Kim, Y. Liu, and J. Wang Dietary Arginine Supplementation Affects Microvascular Development in the Small Intestine of Early-Weaned Pigs J. Nutr., July 1, 2008; 138(7): 1304 - 1309. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Kaul, X. Zhang, T. Dasgupta, and M. E. Fabry Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H39 - H47. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Mateo, G. Wu, H. K. Moon, J. A. Carroll, and S. W. Kim Effects of dietary arginine supplementation during gestation and lactation on the performance of lactating primiparous sows and nursing piglets J Anim Sci, April 1, 2008; 86(4): 827 - 835. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Wu, J. K. Collins, P. Perkins-Veazie, M. Siddiq, K. D. Dolan, K. A. Kelly, C. L. Heaps, and C. J. Meininger Dietary Supplementation with Watermelon Pomace Juice Enhances Arginine Availability and Ameliorates the Metabolic Syndrome in Zucker Diabetic Fatty Rats J. Nutr., December 1, 2007; 137(12): 2680 - 2685. [Abstract] [Full Text] [PDF] |
||||